Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

Background: The SPOTLIGHT trial demonstrated that zolbetuximab plus mFOLFOX6 (ZOL-FO) as a first-line regimen compared with placebo plus mFOLFOX6 (PLB-FO) conferred clinical benefits to patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinom...

Full description

Bibliographic Details
Main Authors: Yufan Huang, Maojin You, Qundan Wu, Ruijia Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
zolbetuximab
CLDN18.2-positive
HER2-negative
gastric or gastroesophageal adenocarcinoma
first-line treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1238009/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1238009/full

Similar Items